SAN DIEGO, Jan. 21, 2014 -- Calbiotech announced today that it is expanding its manufacturing capabilities with the addition of a new GMP monoclonal antibody production facility and the hire of Dr.Jimin Wang, Vice President of Research and Development, who will lead the project.
Antibody production will cater to both Calbiotech and market needs, leveraging strong ties to research and academic groups to identify new markers, produce antibodies and develop assays. Calbiotech will also supplement its strong assay development and contract manufacturing services with custom antibody production services from its GMP facility.
"Calbiotech is excited to break into the antibody sphere with our first production anticipated for release in 2014, and we are thrilled to have Dr. Wang become an integral part of our team," said Calbiotech Vice PresidentDavid Barka.
Wang obtained an MD and PhD from Shanghai Second Medical University, and has more than 15 years of experience working on antibody and assays development. Most recently, he managed the Hybridoma facility for antibody production and a team focused on assay development including cytokine and signaling assays in ELISAs and Luminex platforms at BioSource/Invitrogen.
Calbiotech custom develops and manufactures immunoassay products used by major reference labs, universities and research centers around the world. The company has grown its holdings in recent years, which include Moduline Systems and Calbiotech Veterinary Diagnostics, formed after Calbiotech acquired the veterinary diagnostics division of Meridian Life Sciences, Inc.
"Calbiotech's strategic expansion into antibody production will improve efficiencies, enhance assay development and lead to faster innovation, which benefits our customers and the patients they serve," said Barka.
Calbiotech, Inc. is aSan Diego-based company established in 1998. It specializes in ELISA and Ultrasensitive CLIA assays, featuring more than 200 ready-to-use serum, saliva and research animal ELISA kits.